肝细胞癌组织Glypican3和Sonic Hedgehog蛋白表达及其功能分析*

doi:10.3969/j.issn.1672-5069.2022.01.021

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)组织Glypican3(GPC3)和Sonic Hedgehog(Shh)蛋白表达及其功能分析。方法取96例HCC患者癌组织和癌旁肝组织,体外培养HepG2、MHCC97H、Huh7和SMMC7721细胞,采用免疫组织化学染色法检测组织GPC3和Shh蛋白表达水平,采用免疫荧光染色和蛋白印迹法检测体外培养的肝癌细胞GPC3和Shh蛋白表达,应用String数据库预测GPC3和Shh蛋白之间相互作用。结果在96例HCC癌组织,GPC3和Shh阳性率分别为77.1%和68.8%,而两种蛋白高表达率分别为60.4%和53.1%;高分化HCC癌组织GPC3蛋白阳性率为85.7%,显著高于低分化组的50.0%(P<0.05), Shh蛋白阳性率为81.0%,显著高于低分化组的40.0%(P<0.05);存在微血管侵犯(MVI)的HCC癌组织GPC3蛋白阳性率为72.7%,显著高于无MVI组的50.0%(P<0.05),Shh蛋白阳性率为65.9%,显著高于无MVI组的42.3%(P<0.05);体外培养的HepG2、MHCC97H、Huh7和SMMC7721四种肝癌细胞胞浆GPC3和Shh蛋白共表达,两种蛋白表达趋势一致。结论 GPC3和Shh蛋白可能影响HCC肿瘤细胞分化和MVI形成,并且两种蛋白可能存在共表达及相互作用。

关键词: 肝细胞癌, 磷脂酰肌醇蛋白聚糖3, 声猬蛋白, 免疫组织化学

Abstract: Objective The aim of this study was to investigate the cancerous expression and functional relations of glypican3 (GPC3) and sonic Hedgehog (Shh) proteins in patients with hepatocellular carcinoma (HCC) and hepatoma cell lines in vitro. Methods The expression of GPC3 and Shh in cancerous and adjacent noncancerous tissues in 96 patients with HCC, and in HepG2, MHCC97H, Huh7 and SMMC7721 cells was assayed by immunochemical staining or by immunofluorescence staining and Western blotting. Results The positive rates of GPC3 and Shh protein expression were 77.1% and 68.8%, and the strong expression were 60.4% and 53.1% in our 96 patients with HCC; the positive rate of GPC3 protein in well-differentiated cancerous tissues was significantly higher than that in poorly-differentiated HCC (85.7% vs. 50.0%, P<0.05), and the positive rate of Shh protein was significantly higher than that in poorly-differentiated HCC (81.0% vs. 40.0%, P<0.05); the positive rate of GPC3 protein in cancerous tissues in patients with microvascular invasion (MVI) was significantly higher than that in those without (72.7% vs. 50.0%, P<0.05), and the positive rate of Shh protein was significantly higher than that in those without (65.9% vs. 42.3%, P<0.05); the GPC3 and Shh proteins were consistently co-expressed in the cytoplasm of hepatoma cells in vitro. Conclusion The GPC3 and Shh proteins might affect the differentiation of hepatoma cells and or the MVI formation, and the two proteins might interact each other in the carcinogenesis.

Key words: Hepatoma, Glypican 3, Sonic Hedgehog, Immunohistochemistry

李欢, 李扬, 杜娟, 梅放, 王玉湘, 郭丽梅. 肝细胞癌组织Glypican3和Sonic Hedgehog蛋白表达及其功能分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 83-87.

Li Huan, Li Yang, Du Juan, et al. Cancerous expression and functional relations of glypican3 and sonic Hedgehog proteins in patients with hepatocellular carcinoma and in hepatoma cell lines in vitro[J]. Journal of Practical Hepatology, 2022, 25(1): 83-87.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,30(1):1-41.
[2] 刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展. 实用肝脏病杂志,2021,24(1):7-9.
[3] Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev,2018,38(2):741-767.
[4] Vitale D, Kumar Katakam S, Greve B, et al. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J,2019,286(15):2870-2882.
[5] Wang S, Wang Y, Xun X, et al. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. J Exp Clin Cancer Res,2020,39(1):22-37.
[6] Della Corte CM, Viscardi G, Papaccio F, et al. Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol,2017,23(24):4330-4340.
[7] Gonzalez-Mendez L, Seijo-Barandiaran I, Guerrero I. Cytoneme-mediated cell-cell contacts for Hedgehog reception. Elife,2017,6:e24045.
[8] Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett,2014,588(2):377-382.
[9] Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res,2014,20(24):6418-6428.
[10] Jeng KS, Jeng CJ, Jeng WJ, et al. Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of HCC. Oncol Lett,2019,18(5):4377-4384.
[11] 崔喆,徐兰. 基于多数据库分析肝细胞癌组织FAM49B基因水平及其临床意义. 实用肝脏病杂志,2020,23(3):413-418.
[12] Zhang Q, Lou Y, Yang J, et al. Integratedmultiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut,2019,68(11):gutjnl-2019-318912.
[13] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology,2019,76(2):182-188.
[14] Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol,2017,67(4):727-738.
[15] Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol,2008,129(6):899-906.
[16] Zeng C, Yan R, Yang G, et al. Hedgehog signaling activation required for glypican-6-mediated regulation of invasion, migration, and epithelial-mesenchymal transition of gastric cancer cells. Biosci Rep,2020,40(6): BSR20193181.
[17] Birbrair A. Tumor microenvironment: extracellular matrix components-part A. Adv Exp Med Biol,2020,1245:163-176.
[18] DeRobertis M, Arigoni M, Loiacono L, et al. Novel insights into Notum and glypicans regulation in colorectal cancer. Oncotarget,2015,6(38):41237-41257.
[19] Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol,2014,35:248-252.
[20] Hacker U,Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol,2005,6(7):530-541.
[21] Capurro M, Izumikawa T, Suarez P, et al. Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling. J Cell Biol,2017,216(9):2911-2926.
[22] Li F, Shi W,Capurro M, et al. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol,2011,192(4):691-704.
[23] 吴孟超, 汤钊猷, 刘允怡,等. 原发性肝癌诊疗规范(2019年版). 中国实用外科杂志,2020,40(2):121-138.
[24] Briscoe J,Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol,2013,14(7):416-429.
[25] Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology,2003,125(1):89-97.

肝细胞癌组织Glypican3和Sonic Hedgehog蛋白表达及其功能分析^*

Cancerous expression and functional relations of glypican3 and sonic Hedgehog proteins in patients with hepatocellular carcinoma and in hepatoma cell lines in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[2]	王欣然, 蒋燕东, 张猛. 超声引导下放射性粒子植入治疗肝细胞癌患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 263-266.
[3]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.
[4]	王连双, 张瑶, 单涛, 张记, 吕志斌, 薛明. 19例原发性肝癌心脏转移患者超声特征表现和预后分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 271-274.
[5]	肖倩, 周展, 胡小丽. 肝细胞癌患者肝内病灶超声造影参数变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 92-95.
[6]	中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测[J]. 实用肝脏病杂志, 2021, 24(6): 776-785.
[7]	贾坤, 苏建荣, 孙伟. 慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 823-826.
[8]	吴慧娟, 何年安, 谢蠡, 叶显俊, 章生龙, 刘力. 超声造影联合血清CA19-9鉴别诊断胆管细胞癌与肝细胞癌应用研究[J]. 实用肝脏病杂志, 2021, 24(6): 903-906.
[9]	周正, 刘玮. 肝血管瘤、肝细胞癌和肝血管平滑肌脂肪瘤超声造影特点观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 911-914.
[10]	赵鹏飞, 祖红梅, 辛晓恩, 彭军宁, 严兆兰, 马存凯, 李雅静, 杨硕. 肝细胞癌发病危险因素Logistic回归分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 927-929.
[11]	梁旭, 刘圆圆, 杨学刚, 任静. 基于2018年版肝脏影像报告数据系统对比分析CT和MRI诊断肝细胞癌的效能^*[J]. 实用肝脏病杂志, 2021, 24(5): 725-728.
[12]	赵艺, 卢秉久. 基于TCGA数据库分析肝细胞癌组织UCK2、PRIM1和DNTM1基因水平对患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 729-732.
[13]	张英, 张雷, 丁海涛. TACE术后阿帕替尼维持治疗进展期肝细胞癌患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 733-736.
[14]	于雷, 孙超, 张曼旭. 灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用^*[J]. 实用肝脏病杂志, 2021, 24(4): 476-479.
[15]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.